<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bompas E</submitter><funding>Ligue de L&amp;apos;Ain contre le Cancer, LYric</funding><funding>la Fondation ARC, Infosarcome, InterSARC (INCA), LabEx DEvweCAN</funding><funding>RREPS (INCA)</funding><funding>NetSARC (INCA)</funding><funding>Association DAM&amp;apos;s, Ensemble contre Le GIST, Eurosarc</funding><pagination>4023-4035</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6089183</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(8)</volume><pubmed_abstract>Five-year overall survival (OS) of localized RMS exceeds 70% in children (&lt;18) but is very poor in adult patients. We analyzed the outcome and prognostic factors (PF) of a national series of adult patients with RMS in a large study. The study population consisted of two different cohorts: a retrospective cohort (157 adult patients treated in 13 reference centers between 05/1981 and 02/2010) and the prospective cohort (292 patients with RMS diagnosed and treated between 01/2010 and 12/2014 in France) included in the NetSarc database. A descriptive analysis of patients' characteristics and prognostic factors was conducted on both series which were compared. In the retrospective series, histological subtypes were embryonal (E-RMS) for 21% of patients, alveolar (A-RMS) for 35% of patients, and</pubmed_abstract><journal>Cancer medicine</journal><pubmed_title>Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.</pubmed_title><pmcid>PMC6089183</pmcid><funding_grant_id>ANR-10-LABX-0061</funding_grant_id><funding_grant_id>FP7-278742</funding_grant_id><funding_grant_id>DGOS-INCa-4664</funding_grant_id><pubmed_authors>Piperno-Neumann S</pubmed_authors><pubmed_authors>Soulie P</pubmed_authors><pubmed_authors>Chevreau C</pubmed_authors><pubmed_authors>Isambert N</pubmed_authors><pubmed_authors>Rios M</pubmed_authors><pubmed_authors>Karanian M</pubmed_authors><pubmed_authors>Penel N</pubmed_authors><pubmed_authors>Mir O</pubmed_authors><pubmed_authors>Duffaud F</pubmed_authors><pubmed_authors>Italiano A</pubmed_authors><pubmed_authors>Ray-Coquard I</pubmed_authors><pubmed_authors>Campion L</pubmed_authors><pubmed_authors>Saada-Bouzid E</pubmed_authors><pubmed_authors>Le Cesne A</pubmed_authors><pubmed_authors>Delcambre C</pubmed_authors><pubmed_authors>Blay JY</pubmed_authors><pubmed_authors>Kurtz JE</pubmed_authors><pubmed_authors>Dubray-Longeras P</pubmed_authors><pubmed_authors>Le Loarer F</pubmed_authors><pubmed_authors>Bompas E</pubmed_authors><pubmed_authors>Toulmonde M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.</name><description>Five-year overall survival (OS) of localized RMS exceeds 70% in children (&lt;18) but is very poor in adult patients. We analyzed the outcome and prognostic factors (PF) of a national series of adult patients with RMS in a large study. The study population consisted of two different cohorts: a retrospective cohort (157 adult patients treated in 13 reference centers between 05/1981 and 02/2010) and the prospective cohort (292 patients with RMS diagnosed and treated between 01/2010 and 12/2014 in France) included in the NetSarc database. A descriptive analysis of patients' characteristics and prognostic factors was conducted on both series which were compared. In the retrospective series, histological subtypes were embryonal (E-RMS) for 21% of patients, alveolar (A-RMS) for 35% of patients, and</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Aug</publication><modification>2025-04-21T14:52:54.527Z</modification><creation>2019-03-26T23:51:38Z</creation></dates><accession>S-EPMC6089183</accession><cross_references><pubmed>29956493</pubmed><doi>10.1002/cam4.1374</doi></cross_references></HashMap>